AstraZeneca v Cochran: Amicus Brief of Associations in Support of the Government

Case 1:21-cv-00027-LPS

Document 54

Filed 05/04/21

Pages 1-18 PageID #: 3304-3321

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ASTRAZENECA PHARMACEUTICALS LP,
Plaintiff,

–v–

NORRIS COCHRAN, et al.,
Defendants.

C.A. No. 21-00027 (LPS)

BRIEF OF AMERICAN HOSPITAL ASSOCIATION, 340B HEALTH, AMERICA’S ESSENTIAL HOSPITALS, ASSOCIATION OF AMERICAN MEDICAL COLLEGES, CHILDREN’S HOSPITAL ASSOCIATION, AND AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS AS AMICI CURIAE IN SUPPORT OF DEFENDANTS

Of Counsel:

William B. Schultz (pro hac vice)
Margaret M. Dotzel (pro hac vice)
Casey Trombley-Shapiro Jonas (pro hac vice)
ZUCKERMAN SPAEDER LLP
1800 M Street NW, Suite 1000
Washington, DC 20036
Tel: (202) 778-1800
Fax: (202) 822-8106
wschultz@zuckerman.com
mdotzel@zuckerman.com
cjonas@zuckerman.com

May 4, 2021

LANDIS RATH & COBB LLP
Rebecca L. Butcher (No. 3816) Jennifer L. Cree (No. 5919) 919 Market Street, Suite 1800
Wilmington, DE 19801 Telephone: (302) 467-4400
Facsimile: (302) 467-4450
butcher@lrclaw.com
cree@lrclaw.com

Counsel to American Hospital Association, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, National Association of Children’s Hospitals d/b/a Children’s Hospital Association, and American Society of Health-System Pharmacists Association


Table of Contents

Table of Authorities

Interests of Amici

Introduction

Discussion

  1. The Advisory Opinion Is Consistent with the Plain Meaning and HHS’s Longstanding Interpretation of the 340B Statute
    1. The Plain Meaning of the 340B Statute Requires Drug Manufacturers to Provide Discounts on 340B Drugs Dispensed via Contract Pharmacies
    2. HHS’s Longstanding Interpretation of the 340B Statute Is Consistent with Its Plain Meaning and Supports the Requirement that Drug Manufacturers Provide 340B Discounts on Drugs Dispensed via Contract Pharmacies
  2. The 340B Statute Provides Drug Manufacturers and HHS Effective Tools to Protect Against Diversion and Duplicate Discounts, and AstraZeneca Has No Authority to Impose Limitations on the Availability of Discounts to Address Those Issues

Conclusion